Is thrombolytic therapy underused in women with acute myocardial infarction in clinical practice?  by Burczyk, Udo et al.
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~ Elevated Plasma Angictensin-Convertlng Enzyme 
Levels Are Associated With Myocardial Infarction 
in Young Subjects Without Risk Factors, 
Independently of Coronary Artery Disease, and ow 
Inesrtion/Defation Gene Polymorphlsm 
Ravio R~chini, Gtueeppe Stsffenino, Antonio Dellavalle, 
Teronzio Camilla 1 Alberto Piazza 2, Gabriella Benetton ~, Ping Mafullo 2 
Eugento Uslenghi. Cardiac Catheterization Us#, University of Tudn, I~aly; 
1 Laboratory for CllnicaIBiochemistiy, Copedale S. Croon, Cuneo, University 
of Turin, ifaly; = Institute of Human Genetics, University of Tut~n, Ita~ 
Elevated plasma anglotansin-convsrting enzyme (ACE) levels, and D/D ACE 
genatype have been proposed as risk-factors for myocardial infarction (MI). 
Of 1150 patients (p) wfth MI and no ACE-Inh~ifor treatment undergoing 
coronary a, tsriogrephy in our center during 24 months, 20 p [Group A]wera 
< = 40 year-old and had no conventional dsk factors (CRF) for MI [smoke, 
hypertension, diabetes, body mass index > 26 Kg/m2, Ape B > 1.25 g/L, Lp 
(a) > 20 g/L, fibfinogen > 300 g/L]; 30 p [Group B]were < - 40 year-old and 
had I or > CRR Basal plasma ACE levels were measured with a quantitative 
kinetic determination using FAPGG substrata. Amplification by polymerase 
chain reaction was used in the determination of ACE genotype. Mean (+ - 
SD) plasma ACE levels, and I/D genotype were as follows (percentages in 
brackets): 
No. ACE(U/L) D/D I/D I/I 
Group A 20 30 ~- 13 # 8 (40) 8 (40) 4 (20) 
Group B 30 194.11 # 10(33) 11 (37) 9(30) 
ep. 0.002; 95% c.i. 0.85 to 12 
A normal coronary anglogram (no stsnoals > 20% with Quantitative Coro- 
amy Anglography) was found in 16/20 p in group A vs. none in group B. 
In conclusion: young p with MI and no CRF seem to have higher plasma 
ACE levels than p with CRF. Coronary artery stanesas are often absent at 
angiography in these patients. No significant predominance of the D/D gano- 
type was observed in this limited population sample. The ronin-angiotsnsin 
system may contnloute to the risk of myocandial infarction, with no apparent 
effect on the development of coronary atherosclerosis. 
Acute Myocardial Infarction 
Wednesday, March 27, 1996, 3:00 p.m.--5:00 p.m. 
Orange County Convention Center, Hall E 
Presentation Hour: 4:00 p.m.-5:00 p.m. 
~ - ~  Threatening or Manifest Reocclusion of the 
Infarct Artery in Acute Myocardial Infarction 
Treated With Primary PTCA: Outcome After 
Prolonged Autoperlusionballoon Catheter 
Treatment >_ 30 Minutes 
K. Emmerich, I.. Ulbifcht, I. Krakau, A. Bufe, H. Probst, H. G01ker. Heart 
Center Wuppertal, University of WdforVHerdeske, Germany 
Reeccluslon alter initially successful ropefiuslon of the infarct-ralated coro- 
nary artery ((RA) in acute myocardial infarction (AMI) induces a nearly thrse- 
fold increase of In-hospifat mortality compared to patients (pte) with open 
vessels, The elm of this study was to evaluate the impact of prolonged au- 
toperfualonballcon catheter (APBC) inflation of the IRA on acute and late 
(1S ± 11 months) outcome used in case of thrastaning/manifast reocolualon 
following severe dissuction of a reperfused vessel. Study population and 
charactedst/cs: From ¢2/89 to 10/94 309 pts were treated with primary PTCA 
in AMI within 12 hours of symptom onset. 35 pts.(11.3%) suffered threatening 
(TIMI II) or manifest (TIMI 0/1) reocclusion after initially successful (TIMI III) 
IRA recanallcation. 
Age Male CS Pr/or (%) MVDI" 11me onset of pain 
(years) lots) (%) CABG t MP (%) to recanalication 
58 4.11 32 11 6 26 40 202 4- 90 rain. 
:l:corona,y artery bypass grafting. CS = cardiognnlo shock; "MI - myocardial Infarction; 
tMVD - multk'essel disease 
in 52=/o threatening/manifeet reecclusion ocoured in the fight coronary 
artery [p = 0.326]. APBC used was larger in diameter compared to the 
standard balloon (p ,, 0.0001), APBC inflation pressure lower (p = 0.0001) 
and APBC inflation time longer (mean 35 rain.) [p = 0.0001]. 
Results (%): 
TIMI III- Steals" 30 day EF Q late 
flow (IRA) reooduslon mortallly . (%) restenosla mortality 
94.3 5.7 2.9 5.8"* ÷10 $0,8 O 
• coronary stem after APBC.fa[lura; °'pla in C5 on edmlsalon;~EF - left ventrlcufar elec- 
tion fraction [increase during follow up (p. 0.001)]; 
Conclusions: Prolonged Inflation with an APBC is a safe end successful 
treatment of threatening or manifest reocclualon of the IRA. Improvement of 
EF is significant and restenoals rate is comparable to those in elective PTCA. 
APBC technique seems to be a preferable approach to manage bailout 
s~ations during primary PTCA. 
~ Complementary Beneficial Effect of Early and 
Late Treatment With ACE-Inhlbltora In Acute 
Myocardial Infarction. A Model Based on GISSI-3 
and AIRE Results 
Glullo Zuanet11, Robarto LatiN, Ndo P. Mnggionl, Eugenic Sanforo, 
MafiaGrazla Frenzasl, Giannl Tognonl, on behalf of the GISSI-3 
Invesflgatom. ANMCO and Istitufo M. Negri, Italy 
Several studies documented the beneficial effect of ACE-inhibifors (ACE-i) 
in pta with acute myocardial infarction (AM|). However, selection of pta and 
timing of ACE-I treatment are still debated. We quantified the beneficial effect 
of (a) an early (within 24 hr) use of ACE-I in hemodynamlcally stable pta 
~b) a late use of ACE-Inhlbifors in selected pte and (o) combination of these 
approaches, in 4 different ypes of pts with AMI depending on ~hsence or 
presence of symptoms of cardiac dysfunction at enby (Killlp class > 1) and 
during evolving AMI (CHF+). Actual data on effect of ACE-i were derived 
from GISSI-3 and AIRE studies. The mean time of enrollment of pts in AIRE 
(5 days) was taken as cut-off between early (0-5 days) and late (5 days- 
onward) treatment. The calculated beneficial effect of ACE-! on 8 months 
roortality is as follows 
Clinical status At army Killlp I Kllllp I Killlp > 1 K]llip > 1 
ofpt $ ~ $ ~ 
ln-hosptlal CHF- CHF+ CHF- CHF+ 
% Of AMI pta randomized 74% 8.5% 5% 9% 
within 24 hrs" 
Lives saved Early" 4 4 12 12 
at 0 months/ Late" ~ 21 ~ 21 
1000 ~ts Eady + late 4 25 12 33 
*data derived from GISSI-3, "data dorive{I from AI ~.'-" 
In conclusion, date from a model based on large clinical trials Indicate that 
an early treatment with ACE-i of all hemodynamtcally stable pts with acute 
MI followed by a late targeted treatment of 10ts with symptoms of congestive 
heart failure is able to maximize the benefit of ACE-i in pta with evolving ML 
Is Thrombolyt l¢ Therapy Underuesd In Women 
With Acute Myocardial  In farct ion In Clinical 
Practice? 
Udo Burczyk, J6rg Ruetige, Rudolf Schlale, Armln Koch 1, Dietrich Boppert, 
Jechen Sengas, Herzzentrum Ludwigshafen on behalf of the ALKK Study 
Group. I ZMBT Heldelberg, Germany 
Recent reports have called attention to differences in the therapeutic ap- 
proach of physicians to men end women with acute myocardial infarction 
(AMI). We evaluate the sex-speclflc characteristics of these patients and the 
Influence of gender on dally clinical treatment of AMI. 
Methods: "The 50-Minutes Myocardial Infarction Project" is s mulflcenter 
nationwide study of current treatment of AMI which includes 136 hospitals 
in Germany. During a 27-month pedod 14 980 patients with proven trans. 
mural AMI were enrolled and lysls rate (LR), prehospifal delay, absolute and 
relative contraindications to thrombolyals and the diagnostic accuracy of the 
electrocardiogram upon admission were studied. 
Results: 
Men (n - 10 209) Women (n = 4 771) 
Age (mean/yr) 82 71 * 
Lysia rate (%) 58 42" 
Pmhospital delay (medianJh) 2.6 3.5" 
Contraindlcatlons (%) 22 23 
Diagnostic ECG (%) 72 71 
• p < 0.05 
A multivariate analysis of 15 factors associated with indication to thmm- 
bolyals showed that female sex was an independent predictor of a lower LR 
(Odds ratio: 0.8; g5%-confidence interval: 0.7-0.9). 
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Conc/usiona: 1. Women with AMI are less often treated with thrombolytic 
agents compared with male patients. ,?. Major reasons: women wore nearly 
one decade older and arrived later to the CCU after onset of symptoms. 3. De- 
spite the higher age women showed an equal frequency of contraindications 
and no difference in the diagnostic accuracy of the ECG upon admission. 4. 
After accounting for other dilfomnces, female sex was independently asso- 
dated with a lower LR. This is presumably caused by an underestimation f
the probability of AMI or the benefits of thrombolytic therapy in women by 
physicians. 
~ D o s s  the Presence or Absence of  Pain at Chest 
Initiation of  Thrombolysis In Acute Myocerdlal 
Infaretion Affect OUtcome? 
David A. Vorchhaimer, Lawrence Bamch, Mardck L Kukin, Karan S. Pisper, 
Chdstopher B. G~,  Edc J. Topoi, Robert M. Califf on behalf of the 
GUSTO-I Investigators. Mount Sinai Medioaf Center, New York, IVY; Duke 
Coordinating Center, Durham, NC 
Dudng acute myocardial infarction (AMI) chest pain may resolve sponta- 
neously or following nitrates or opiates. When symptoms resolve, clinicians 
may avoid thrembolysts. To determine outcomes in patients (pts) who present 
with ongoing electrocardiographic signs of AMI, but CP free, North American 
pts enrolled in the GUSTO-I study wore divided according to presence or 
absence of CP at onset of thmmbelysis. Pain-free pts were older (62,8 vs. 
60.3 years), lighter weight (80.2 vs, 81.6 kg), more often female (32% vs. 
26%), hypertensive (46°/,, vs. 41%), with pdor MI (21% vs. 16°/,); all p < 
0,001.incidence of diabetes was comparable (17% vs. 16%, p = NS). 
Event Pain-Present Pain-Free P value 
(n = 22,426) (n - 1,316) 
Confirmed MI 21932 (98%) 1210 (92%) <0.001 
In-hospitaldeath 1016 (5%) 70 (5%) 0.181 
30 day mortality 1089 (5%) 75 (6%) 0.157 
Reinfarctlen 864 (4%) 59 (4%) 0.248 
Shock 1171 (5%) 65 (5%) 0.659 
CHF/Pulm Edema 3844 (17%) 208 (16%) 0.215 
Stroke 321 (1.4%) 34 (2.6%) 0.001 
Pain-free pts had similar outcomes compared with Path-present; he higher 
stroke incidence is likely attributable to differences in baseline variables. 
Thus, absence of ongoing CP should not preclude lytic administration i pts 
with electrocardiographic evidence of AMI. 
~ Paromedic Diagnosis Myoc~d~!  ECG ol4 
infarction With Direct Admiss ion to Coronary 
Care Results in Reduction in Delay to 
Thrombolysls  
Michael W. Mittar-Craig, Alice V. Joy, Margaret B. A~icz ,  
Roland Furber, Barry Thomas 1 Derbyshire Royal Infirmary,, Derby, United 
Kingdom; 1 Derbyshire Ambulance Service, Derby, United Kingdom 
Aim:To reduce thrombelytic trea~nent delay after myocardial infarction (MI). 
Methods: A prospective study was carded out in which paramedics wore 
trained to record and interpret a standard 12-lead ECG when called to 
suspected MI patients. Dudng the initial training phase (Ph I), ECGs wore 
recorded and patients wore taken to the hospital Emergency Department 
(ED) with subsequent ransfer to the Corenary Care Unit (CCU) for throrn- 
belytic therapy, where appropriate, after assessment by casualty and ad- 
mitting medical staff. Phase II (Ph II) commenced when satisfactory ECG 
recording and interpretative skills had been achieved by paramedics. Dudng 
Ph II, patients with ECG evidence of acute MI or Ischeemia were admitted 
directly to CCU by paramedics using a radio link with CCU. All other patients 
wore taken to the ED in the usual way. Threugheut the study, paramedic 
ECGs wore scored for technical quality and accuracy of interpretation by a 
cardiologist. 
Results: Average accuracy of ECG diagnosis by the paramedics was 
87.5,='0 in Ph I and 92% in Ph II. In Ph i, 123 patients were admitted to CCU 
via the ED, of whom 63 (51"/o) had confirmed MI. In Ph II, 124 patients wore 
admitted irectly to CCU, and MI was confirmed in 71 (57%). One patient In 
Ph II, whose initial paramedic ECG was normal, was taken to the ED where 
MI was subsequently dingnocad. None of the remaining 38 Ph II patients 
taken to the ED with negative ECG sustained MI. 
Mean delay times (minutes) for patients who received thrombolytic therapy 
are shown below. 
Call-site On site 81te.hosp Door-needle Total time 
Phase I 10 30 17 97 154 
Phase II 9 (NS) 31 (NS) 16 (NS) 37 = 93" 
Phase I v Phase II *p < 0.001 (Mann-Wh~ey U test) 
Conclusion: Ao~urate and early diagnosis of MI can be achieved with a 
trained paramedic service, resulting kl == sc~.'stantial reduction in thrombolysis 
delay times. 
~ Early Acednhlbit ion in Patlente With Q- and 
Non-Q Wave Acute Anterior Myocardial Infarction 
Claudio Borghi, Ettore Ambmsioni, Bruno Magnani, for the SMILE 
Investigators. University of Bologna-italy 
The early treatment with the ace-inhibitor zofenopd! has resuff'~:l beneficial in 
patients with acute ML The role of infarct location on mortality and prevalence 
of severe CHF has been evaluated in the SMILE population subdivided in 2 
groups identified by the presence or absence of Q waves in the baseline EKG 
evaluation. The 2 groups of patients were comparable at baseline whereas 
the event rate was greater in patients with Q-wave MI. Zofanopril lmatment 
reduced significantly the 6-woak prevalence of major CV everCs (Death + 
severe CHF) only in patients with Q wave MI. One year mortality was signifi- 
cantly reduced in patients with Q-wave MI by Veatmant with zofenopdl (RR 
40%; 95% C.I, 13-58). No effect on long-term mortality has been observed 
in patients with non-Q wave MI. 
G-week 1 -year 
%Mort;dity %Death + CHF %Moffality 
Plac Zof Plec Znt Plac Zof 
Q w'a~e MI (n = 1270) 7.s 6.0 9.1 6.3" 18.6 12.1" 
Non-Q wave (n = 251 ) 1.0 0.7 1.5 0.9 14.0 14.1 
"p < 0.005 vs Placebo 
We conclude that the benefit of early acs-infiibition can be strongly is 
enhanced in patients with Q wave MI. 
~ Plasma Plasmlnogen Activator-1 Level (PAF1 L) 
Increase After Thrembolyt lc Therapy. A 
Randomized-Controlled Study W~:h 
Stmptoklnase (SK) and Recembina~: T~;ue-Type 
Plasminogen Activater (rt-PA). 
Fransk Paganelli 1, Made C. Alessi 2 Jean M. Malxent 1,/Main Saadjjian 1 
Samuel Levy I , Irene Juhen-Vague 2.1 Division of Cardiology, School of 
Medicine, Marseille, France: 2 Deparfment of Hae~ School of 
Medicine, Marseille, France 
PAl-1 plays an important role in regulating fibrinolysF,;. F )q~fiments in animals 
have shown that modulation of PAl-1 activity in plasma influence thrombosis. 
, It have been previously shown that PAl-1 L increase after rtPA injection in 
vivo. Whether or not this rebound is tPA specir¢ is not known. Reasons 
for resistance to thmmbelysis may be antifibdnolytic rebound phenomenon 
after thrombolylJc therapy (TI'). Our aim was to compare volution of PAl-1 L 
after rtPA and SK administration. PAl-1 activity and antigen were measured 
sedally (0, 3, 6, 12, 18, 24, 48 hours) in 53 cons~ patients (tots) 
with acute myocardial infarction (AMI). After randomization, 28 pts received 
inVevanously SK (1.5 Million Units) and 25 pts rt-PA aocom3ng to GUSTO. 
Hours PAl-1 ant~en (ng/rnl) PAl-1 activ~ (U//ml) 
rt-PA SK ft-PA SK 
0 (before TI") 444-8 38<-7 194-3 154-3 
.,I ~14 484-8 284-3 174-3 
6 574-7 854-7 234.2 30<-4 
12 44~-5 1;22:1:12 184-2 354-4 
18 434-4 984-10 184-2 384-4 
24 404-4 594-9 164-1 254-3 
48 404-7 404-1 184-3 144-2 
PAl-1 L are markedly increased after SK or rt-PA in AMI. The peak of 
PAl-1 L is higher and occurs later with SK than with rt-PA. These results 
could explain partially slower activity of SK to open occluded a~ery with SK 
compan~l to tlPA. Supported by French Heart Society 
~ Pre-Hospitat In the Second Eleatrecerdlogram 
National Registry of  Myocerdlal Infarction 
(NRMI-2) 
John G. Canto, William J. Rogers, Laura J. Bowrcy, William J. French, 
Douglas J. Pearce, for the NRMI-2 Invas~gators. University of Alabama 
Medical Canter, Birmingham, AL 
The prehospltal electrocardiogram (PH-ECG) has been proposed as a 
means for rapidly identifying patients wkh acute myocardial infarction (AMI) 
who might be eligible for repedusion interventions. Inorder to ascertain char- 
actedstics and outcomes of AMI patients having PH-ECG's, data from the 
ongoing NRMI-2 wore analyzed. 
~E 
